Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on CAPMAN OYJ-B SHS. We currently have 0 research reports from 0 professional analysts.
|21Feb17 10:01||GNW||CapMan has published its 2016 Annual Report|
|16Feb17 06:30||GNW||CapMan's subsidiary Norvestia exits Idean Enterprises Oy - another success for the Growth Equity team|
|02Feb17 06:35||GNW||CapMan establishes a new investment area, CapMan Infra|
|02Feb17 06:30||GNW||CapMan Plc's 2016 results improved significantly|
|26Jan17 07:31||GNW||CapMan to publish its Financial Statements Bulletin 2016 on Thursday 2 February 2017|
|29Dec16 08:30||GNW||CapMan Real Estate advises BVK on the acquisition of three residential properties in a growing area in Copenhagen|
|22Dec16 10:00||GNW||CapMan Plc issues shares to Norvestia Oyj's shareholders who had accepted the exchange offer during the offer period|
Frequency of research reports
Research reports on
CAPMAN OYJ-B SHS
CAPMAN OYJ-B SHS
Another positive verdict
20 Mar 17
Burford’s results for 2016 produced another outstanding set of figures. Revenue grew by 60% to $163.4m with strong growth in the litigation finance business and an additional boost from a secondary sale in the Petersen case. On an underlying basis net income grew to $114m, a 75% increase despite the investment in growing capacity which increased costs. A combination of ongoing investment and gains and increases on valuation saw the fair value of the litigation assets increase 67% to $559m, underpinned by a growth in invested capital to $394m. With the results statement there was an announcement of a further sale of 9% of the Petersen case at a valuation of 20 times the cost of investment.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
Small Cap Breakfast
21 Mar 17
First Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march. Tufton Oceanic Assets- The Company intends to invest in a diversified portfolio of second hand commercial sea-going vessels where the Investment Manager believes that an attractive opportunity exists in shipping. $150m raise. Admission 3 April.